Coxsackievirus B4 polyprotein (CVB4)

Coxsackievirus B serotype 4 (CVB4) is a significant human pathogen within the Enterovirus B species of the Picornaviridae family (UniProt P03313). The CVB4 polyprotein is a large precursor molecule that is proteolytically processed into four structural proteins (VP1, VP2, VP3, and VP4) which form the viral capsid, and seven non-structural proteins (2A, 2B, 2C, 3A, 3B, 3C, and 3D) involved in viral replication and host cell modulation. CVB4 is of particular interest in biotechnology due to its strong epidemiological and mechanistic link to the development of Type 1 Diabetes (T1D), as it can infect pancreatic beta cells and potentially trigger autoimmune destruction (PMID: 33106326). Therapeutic interventions targeting CVB4 antigens include polyvalent vaccines like PRV-101, which aim to prevent T1D by inducing neutralizing antibodies against the viral capsid (ClinicalTrials.gov NCT04690426). Additionally, antiviral agents such as pleconaril target the capsid to prevent viral uncoating, while inhibitors like rupintrivir target the 3C protease to halt the viral life cycle (PubChem CID 102011).

Other names

Coxsackievirus B serotype 4 antigensCVB4 capsid proteinsEnterovirus B4 polyproteinCoxsackie B4 virus proteins

Neutralization of viral particles by antibodies; inhibition of viral uncoating via capsid binding; inhibition of viral 3C protease activity; inhibition of RNA-dependent RNA polymerase.